No products in the cart.
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
Tag: BRAF-mutated melanoma
Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to ...
First-line treatment with immune checkpoint inhibitor rather than BRAF and MEK leads to improved survival
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2. ...
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events
Click to read the study in Clinical Cancer Research.
#VisualAbstract: Encorafenib plus binimetinib improves quality of life outcomes compared to vemurafenib in patients with advanced BRAF-mutated melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients
Click to read the study in the European Journal of Cancer.
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.